Keymed Biosciences, Inc. (HK:2162) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Keymed Biosciences Inc. reports a significant downturn in its interim results for the first half of 2024, with revenue plummeting by 83% and an increase in net loss by 799% compared to the same period in 2023. The company’s research and development expenses rose by 33%, deepening the financial losses. Despite the decline, Keymed maintains a cash reserve, though reduced by 5% from the end of the previous year.
For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.